http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20080051578-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95363fc2cf0b49e7a4aef32d7cb692a1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 |
| filingDate | 2006-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba8fc181af653e083dfe853ef8fc970a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b38da978a0efa4c89847b83aea62de0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f48579f2230fefe507c96d6f8bdeaf17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7a2b390a8b3dc8189fa461e782452c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88aacdb7797582d058d74cffb9b5f557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73db3d3629bd04675d3027bf7471af96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bcb2936465abb107db881e5f9be8ce9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09bcf0289472315bebe58bb0d5b2a9bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb33526d644bd9feea1dcbecc0850b7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af1305f037c124e3a6f91d5e57647036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01a8f27e38d57af2790beb4b3b42d82b |
| publicationDate | 2008-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20080051578-A |
| titleOfInvention | Polynucleotide containing CsylLTR2SNP for diagnosing aspirin-sensitive asthma (AIIA) |
| abstract | The present invention is a polynucleotide consisting of the DNA sequence of SEQ ID NO: 1, 20-30 consecutive DNA sequence, characterized in that the 30th (locus corresponding to -819 locus of the CYSLTR2 gene) is T and comprises the T base Polynucleotide consisting of; In a polynucleotide consisting of the DNA sequence of SEQ ID NO: 2, the 30th (locus corresponding to +2078 locus of CYSLTR2 gene) base is T and consists of 20-30 consecutive DNA sequences, characterized in that it comprises the T base. Polynucleotides; And a polynucleotide consisting of the DNA sequence of SEQ ID NO: 3, wherein the 30th (locus corresponding to +2534 locus of CYSLTR2 gene) base is G and comprises 20-30 consecutive DNA sequences comprising the G base In particular, the sequence of the locus located in the promoter or 3'-UTR of the CysLTR2 gene affects the transcriptional efficiency of the CysLTR2 gene or mRNA stability, and thus the possibility of aspirin hypersensitivity in asthmatic patients. It relates to a polynucleotide that functions as a biomarker to predict. The expression of CysLTR2 protein is higher in the B cell line of asthma patients with ht2 + / + than in patients with ht1 + / +, and PMA / ionomycin is asthmatic with ht2 + / + than in patients with ht1 + / +. MRNA expression is further induced in B cell line of the patient. Nuclear extracts from the B cell line exhibited stronger DNA binding affinity with probes containing c-819T than probes containing c-819G, and luciferase activity of the CYSLTR2 promoter c-819T type was luciferase of type c-819G. It is higher than activity, and EGFP expression is higher in EGFP-c2078T 3'UTR fusion structure than in c2078C structure. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010013855-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101134853-B1 |
| priorityDate | 2006-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 384.